美國Dynavax Technologies
流感疫苗 Dynavax技術公司是一家臨床階段的生物制藥公司,致力于發現和開發新產品,以預防和治療感染性疾病。
Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company committed to discovering and developing novel products to prevent and treat infectious diseases. Our clinical-stage product candidates include:
Phase 3 HEPLISAV ? Hepatitis B Vaccine
Phase 1 Hepatitis C Therapy
Phase 1 Hepatitis B Therapy
In addition, we are developing a preclinical Universal Flu vaccine and programs partnered with pharmaceutical companies, including AstraZeneca and GlaxoSmithKline.
Our European subsidiary Rhein Biotech manufactures hepatitis B surface antigen for HEPLISAV. With 20 years in business, Rhein Biotech also provides integrated product development services to enable its partners to bring products to market.